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Alkylation of DNA and RNA is a potentially toxic lesion that
can result in mutations and even cell death. In response to
alkylation damage, K63-linked polyubiquitin chains are
assembled that localize the Alpha-ketoglutarate-dependent
dioxygenase alkB homolog 3–Activating Signal Cointegrator
1 Complex Subunit (ASCC) repair complex to damage sites in
the nucleus. The protein ASCC2, a subunit of the ASCC
complex, selectively binds K63-linked polyubiquitin chains via
its coupling of ubiquitin conjugation to ER degradation (CUE)
domain. The basis for polyubiquitin-binding speciﬁcity was
unclear, because CUE domains in other proteins typically bind
a single ubiquitin and do not discriminate among different
polyubiquitin linkage types. We report here that the ASCC2
CUE domain selectively binds K63-linked diubiquitin by contacting both the distal and proximal ubiquitin. The ASCC2
CUE domain binds the distal ubiquitin in a manner similar to
that reported for other CUE domains bound to a single ubiquitin, whereas the contacts with the proximal ubiquitin are
unique to ASCC2. Residues in the N-terminal portion of the
ASCC2 α1 helix contribute to the binding interaction with the
proximal ubiquitin of K63-linked diubiquitin. Mutation of
residues within the N-terminal portion of the ASCC2 α1 helix
decreases ASCC2 recruitment in response to DNA alkylation,
supporting the functional signiﬁcance of these interactions
during the alkylation damage response. Our study reveals the
versatility of CUE domains in ubiquitin recognition.

Ubiquitylation is a reversible, posttranslational modiﬁcation that regulates a vast array of cellular processes including
proteasomal degradation, transcription, and the DNA damage response (1–3). The ubiquitin C-terminus is conjugated
to protein substrates in a cascade of enzymatic reactions,
most commonly forming a covalent linkage with the ε-amino
* For correspondence: Patrick M. Lombardi, p.m.lombardi@msmary.edu;
Cynthia Wolberger, cwolberg@jhmi.edu.

group of a lysine side chain or the N-terminal α-amine (4).
Ubiquitin itself can be ubiquitinated via one of its seven
lysine residues or at its amino terminus, giving rise to
homotypic or branched polyubiquitin chains with distinct
topologies and biological functions (5). Different types of
polyubiquitin chains are recognized by domains or motifs
that bind speciﬁcally to the particular ubiquitin modiﬁcation,
thereby recruiting downstream effector proteins (6). In this
manner, the diversity of ubiquitin signaling is predicated on
the ability of ubiquitin-binding proteins to differentiate
among the myriad types of polyubiquitin modiﬁcations present in the cell.
Lysine 63 (K63)-linked polyubiquitin chains play a nondegradative role in several DNA damage response pathways,
including the response to DNA alkylation (2, 7). The E3
ubiquitin ligase, RNF113A, assembles K63-linked polyubiquitin chains at the sites of alkylation damage (7). These
polyubiquitin chains recruit the Alpha-ketoglutaratedependent dioxygenase alkB homolog 3 (ALKBH3)–ASCC
complex, which repairs the lesions (7). A subunit of the
complex, ASCC2, binds to the K63-linked polyubiquitin chains
via its coupling of ubiquitin conjugation to ER degradation
(CUE) domain, a ubiquitin-binding domain of approximately
50 amino acids (Fig. 1) (8, 9). As shown for Cue1, Cue2, gp78,
and Vps9, CUE domains bind the hydrophobic I44 patch of
ubiquitin via conserved hydrophobic sequence motifs (Fig. 1B)
(8–11). These sequence motifs are conserved in ASCC2, suggesting that its CUE domain binds ubiquitin in a similar
manner. Indeed, substitution of ASCC2 residue L506, which
lies in the predicted ubiquitin-binding patch, abrogates
ubiquitin-binding in vitro and dramatically reduces the formation of ASCC2 nuclear foci in response to alkylation
damage (7). Coupling of ubiquitin conjugation to ER degradation domains typically make extensive interactions with a
single ubiquitin within a polyubiquitin chain and exhibit
little selectivity among different types of polyubiquitin chains
(8–10, 12). It is not known what other ASCC2 surfaces
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The ASCC2 CUE domain binds two adjacent ubiquitins

Figure 1. The ASCC2 CUE domain. A, the ASCC2 CUE domain folds into a three-helix bundle. B, CUE domains contain conserved sequence motifs on the α1
and α3 helices (in bold, below asterisks) that form a hydrophobic ubiquitin-binding surface (yellow sticks in A). ASCC2, Activating Signal Cointegrator 1
Complex Subunit 2; CUE, coupling of ubiquitin conjugation to ER degradation.

mediate interactions with ubiquitin and specify binding for
K63-linked polyubiquitin.
We report here that the ASCC2 CUE domain binds with
higher afﬁnity to K63-linked polyubiquitin as compared to
monoubiquitin or other types of polyubiquitin chains. Using
solution NMR, we show that a single ASCC2 CUE domain
makes distinct contacts with the two adjacent ubiquitins
within a single K63-linked polyubiquitin chain. In addition to
mediating conserved interactions with the I44 patch of the
distal ubiquitin, a separate region of the ASCC2 CUE domain
forms additional interactions with the proximal ubiquitin in
K63-linked polyubiquitin. Mutations in the ASCC2 CUE
domain residues that contact the proximal ubiquitin disrupt
recruitment of ASCC2 to repair foci, consistent with the
importance of these residues in binding to K63-linked polyubiquitin. Together, our data show that the ASCC2 CUE
domain makes multiple, linkage-speciﬁc interactions with
adjacent ubiquitins to enhance the afﬁnity of the ALKBH3–
ASCC complex for K63-linked polyubiquitin chains at alkylation damage sites.

Results
The ASCC2 CUE domain has enhanced afﬁnity and speciﬁcity
for K63-linked polyubiquitin chains
The ASCC2 CUE domain comprises a three-helix bundle
that spans residues 465 to 521 (Fig. 1). The solution structure
of the ASCC2 CUE domain has been deposited in the Protein
Data Bank (PDB ID: 2DI0) (Fig. 1A) and is similar to other
experimentally determined CUE domain structures. The
structure of the ASCC2 CUE domain superimposes with the
Cue2 CUE domain (PDB ID: 1OTR) (8) with an RMSD of
0.92 Å over 37 alpha carbons and with the gp78 CUE domain
(PDB ID: 2LVN) (10) with an RMSD of 1.34 Å over 41 alpha
carbons. Like other CUE domains, ASCC2 has a cluster of
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hydrophobic residues on helix 1 and on helix 3, which are
predicted to bind to the I44 patch of ubiquitin as in previously
characterized CUE:ubiquitin interactions (8–12) (Fig. 1B). The
previous ﬁnding that a substitution at L506 in helix 3 leads to
defects in ASCC2 recruitment in cells (7) is consistent with a
role for this surface in ASCC2 binding to ubiquitin.
To determine whether the ASCC2 CUE domain binds in a
similar manner to ubiquitin irrespective of whether it is
incorporated into a polyubiquitin chain, we used isothermal
titration calorimetry (ITC) to compare binding of ASCC2 CUE
domain constructs to monoubiquitin and K63-linked diubiquitin (K63Ub2). As shown in Figure 2, A and B, we found that
the ASCC2 CUE domain binds with lower afﬁnity to monoubiquitin than to K63Ub2. The equilibrium dissociation constant (Kd) for monoubiquitin was 57.1 μM ± 5.0 μM (Fig. 2A),
whereas ASCC2 bound much more tightly to K63Ub2, with a
Kd of 8.7 μM to 10.4 μM (Fig. 2B). The afﬁnity of the isolated
ASCC2 CUE domain for K63Ub2 is similar to that of fulllength ASCC2, which binds to K63Ub2 with a Kd of
8.8 μM ± 0.9 μM (Fig. 2C). The similar equilibrium dissociation constants suggest that the majority of the afﬁnity comes
from the interaction between the CUE domain and K63Ub2.
Importantly, the approximately 4- to 7-fold enhancement of
ASCC2 CUE domain afﬁnity for K63Ub2 as compared to
monoubiquitin is higher than the 1.0- to 1.8-fold enhancement
in afﬁnity that has been reported for other CUE domains
binding to polyubiquitin versus monoubiquitin (10, 11).
Because very weak binding is difﬁcult to measure accurately
by ITC, we also estimated the afﬁnity of the ASCC2 CUE
domain for monoubiquitin using NMR spectroscopy. The
1 15
H, N-Heteronuclear Single Quantum Coherence (HSQC)
spectra of 15N-labeled ASCC2(465–521) were recorded in the
presence of increasing amounts of monoubiquitin, and the
chemical shift perturbations (CSPs) for four ASCC2 residues at
the ubiquitin-binding interface were used to calculate the
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Figure 2. The ASCC2 CUE domain binds K63Ub2 with enhanced afﬁnity and 1:1 stoichiometry. A–C, ITC data show that full-length ASCC2 and isolated
ASCC2 CUE domain bind K63Ub2 with greater afﬁnity than monoubiquitin (Ub). D, two ASCC2 CUE domains bind per K63-linked tetraubiquitin chain
(K63Ub4). This 1:1 ASCC2 CUE domain to K63Ub2 ratio is observed in B and C as well. E, the ASCC2 CUE domain does not exhibit enhanced-binding afﬁnity
for linear diubiquitin (M1Ub2) or (F) K48-linked diubiquitin (K48Ub2). ASCC2, Activating Signal Cointegrator 1 Complex Subunit 2; CUE, coupling of ubiquitin
conjugation to ER degradation; ITC, isothermal titration calorimetry.

average Kd value (Fig. S1) (13). The Kd value of 39.6 μM ±
1.6 μM determined by NMR suggests somewhat tighter
monoubiquitin binding than the Kd determined by ITC

(57.1 μM ± 5.0 μM Fig. 2A), although still substantially weaker
than that measured for K63Ub2 (Kd = 8.7 μM–10.4 μM
Fig. 2B).
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The stoichiometry of the ASCC2 CUE domain binding K63linked polyubiquitin chains is also different from that of previously studied CUE domains. CUE domains from other
ubiquitin-binding proteins, such as gp78, bind diubiquitin with
a ratio of two CUE domains per diubiquitin (10), indicating
that each CUE domain binds to one ubiquitin in the diubiquitin chain. The ASCC2 CUE domain, however, binds
K63Ub2 in a 1:1 ratio (Fig. 2B), and this ratio is conserved in
the binding of full-length ASCC2 to K63Ub2 (Fig. 2C).
Importantly, the observed molar ratio of one ASCC2 CUE
domain per K63Ub2 is preserved in the context of longer
polyubiquitin chains. As shown in Figure 2D, the ASCC2 CUE
domain binds to K63-linked tetraubiquitin with a molar ratio
of 2:1, consistent with each CUE domain binding to two
ubiquitins within the tetraubiquitin chain. Interestingly, the
afﬁnity of the ASCC2 CUE domain for K63-linked tetraubiquitin is about 4-fold higher than its afﬁnity for diubiquitin
(Fig. 2, B and D).
To test the speciﬁcity of ASCC2 for K63-linked diubiquitin
as compared to other linkage types, we measured the Kd of the
ASCC2 CUE domain for linear and K48-linked diubiquitin
(K48Ub2). The afﬁnity of the ASCC2 CUE domain for linear
diubiquitin (M1Ub2) was extremely weak, with a Kd of about
400 μM (Fig. 2E). This result was surprising given that linear
and K63-linked polyubiquitin adopt a similar extended topology (14, 15). The afﬁnity of the ASCC2 CUE domain for
K48Ub2 (Fig. 2F), with a Kd of about 98 μM, was similar to that
measured for monoubiquitin. These results indicate that the
enhanced binding afﬁnity of the ASCC2 CUE domain for
polyubiquitin compared to monoubiquitin is speciﬁc to K63linked chains.

tail of ubiquitin. The similar CSP values suggest the distal
ubiquitin of K63Ub2 binds the ASCC2 CUE domain using the
same surface as previously reported CUE:ubiquitin interactions (10, 11).
The CSP values for the 15N-labeled proximal ubiquitin of
K63Ub2 titrated with ASCC2(465–521) (Fig. 3D), however,
were markedly different from those observed for the
15
N-labeled distal ubiquitin. The CSP values for ubiquitin
residues V70, R72, L73, and R74 were smaller in the experiments with 15N-labeled proximal ubiquitin (Fig. 3D) as
compared to the experiments with 15N-labeled distal ubiquitin
(Fig. 3C). In addition, large CSP values for residues E64 and
T66 (Fig. 3D) were unique to the proximal ubiquitin. The large
CSP values for proximal ubiquitin residues E64 and T66 and
the small CSP values for residues in the ubiquitin C-terminal
tail suggest that the ASCC2 CUE domain contacts the proximal ubiquitin in a noncanonical manner. The differences
between the distal and proximal ubiquitin CSP values suggest
that the two ubiquitins use different surface residues to
interact with the ASCC2 CUE domain (Fig. 3, E and F).
To determine the contribution of proximal ubiquitin residues E64 and T66 to ASCC2 CUE domain binding, we
measured the afﬁnity of the ASCC2 CUE domain for K63Ub2
bearing side chains substitutions at proximal ubiquitin residues E64 and T66 (K63Ub2 E64A/T66Aprox) using ITC. As
shown in Figure 4, the ASCC2 CUE domain binds K63Ub2
E64A/T66Aprox with a Kd in the range of 45.9 μM to 90.9 μM,
approximately 3.5 to 7.0 times more weakly than WT K63Ub2.
This result supports the NMR data (Fig. 3B) in suggesting that
the ASCC2 CUE domain interacts with residues E64 and T66
of the proximal ubiquitin in K63Ub2.

The ASCC2 CUE domain forms different contacts with the
distal and proximal ubiquitin of K63Ub2

The N-terminal portion of the ASCC2 α1 helix is important for
K63-linked polyubiquitin binding and recruitment to DNA
damage foci

The higher afﬁnity of ASCC2 for diubiquitin or tetraubiquitin and the molar ratio of one ASCC2 CUE domain per
diubiquitin are consistent with a single CUE domain simultaneously contacting the linked proximal and distal ubiquitin.
Given the small size and asymmetric fold of the CUE domain,
ASCC2 would need to form different binding interfaces with
the two ubiquitin monomers. We used NMR chemical shift
mapping experiments to compare ASCC2 CUE domain
contacts with the distal and proximal ubiquitins of K63Ub2.
To distinguish the two covalently linked ubiquitin monomers,
we generated diubiquitin with either the proximal or
the distal ubiquitin isotopically labeled with 15N. The
1
H,15N-HSQC spectra of the differently labeled K63Ub2 were
recorded in the presence of increasing concentrations of the
ASCC2 CUE domain (Fig. 3, A and B). The CSP values for the
15
N-labeled distal ubiquitin of K63Ub2 titrated with the
ASCC2 CUE domain (Fig. 3C) are similar to those reported
for other CUE domains interacting with monoubiquitin
(10, 11). The common features include relatively large CSP
values for residues in and around the I44 patch, such as R42,
I44, G47, and K48, and for residues 70 to 74 at the C-terminal
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To determine which ASCC2 residues interact with
K63-linked polyubiquitin, the 1H,15N-HSQC spectra of
15
N-labeled ASCC2 CUE domain were recorded in the presence of increasing concentrations of monoubiquitin and
K63Ub2 (Fig. 5). ASCC2 residues L479 and L506, from the
conserved CUE domain hydrophobic sequence motifs in the
α1 and α3 helices, respectively, exhibited large CSP values
when the ASCC2 CUE domain was titrated with monoubiquitin or K63Ub2 (Fig. 5, A–D). This ﬁnding suggests that,
as with other CUE domains (8–12), the hydrophobic surface
created by the conserved sequence motifs is the binding site
for monoubiquitin and one of the ubiquitins in K63Ub2. The
distal ubiquitin of K63Ub2 is most likely to bind the hydrophobic surface formed by the conserved sequence motifs given
the similarities between its CSP values (Fig. 3C) and those
reported for monoubiquitin titrated with other CUE domains
(10, 11).
The ASCC2 residues that interact with the proximal
ubiquitin of K63-linked diubiquitin would be expected to
have larger CSP values when the CUE domain is titrated with

The ASCC2 CUE domain binds two adjacent ubiquitins

Figure 3. The ASCC2 CUE domain makes different interactions with the distal and proximal ubiquitins of K63Ub2. Regions of the 1H,15N-HSQC
spectra for the 15N-labeled distal (A) and proximal (B) ubiquitins of K63Ub2 titrated with the ASCC2 CUE domain suggest different residues from each
ubiquitin contact ASCC2. For example, the resonances for residues E64 and T66 disappear during the titration with the ASCC2 CUE domain for the
15
N-labeled proximal ubiquitin (B) but show modest shifts for the 15N-labeled distal ubiquitin (A). The CSPs values for all residues from 15N-labeled distal and
proximal ubiquitins of K63Ub2 titrated with the ASCC2 CUE domain are reported in panels C and D, respectively. Black bars indicate the resonance disappeared during the titration, and the “I” in D denotes the K63Ub2 isopeptide bond. Highlighting residues with CSP values greater than 1σ (yellow) and 2σ
(red) on the surface of the distal (E) and proximal (F) ubiquitins suggest that ASCC2 makes different contacts with the distal and proximal ubiquitins of
K63Ub2. ASCC2, Activating Signal Cointegrator 1 Complex Subunit 2; CSP, chemical shift perturbation; CUE, coupling of ubiquitin conjugation to ER
degradation; HSQC, Heteronuclear Single Quantum Coherence.

K63Ub2 than when it is titrated with monoubiquitin. The α1
helix (residues 465–479; Fig. 1A) is the only region of the
ASCC2 CUE domain that has dramatically different CSP
values in the presence of K63Ub2 compared to monoubiquitin (Fig. 5, A–D). The majority of residues from the
N-terminal end of the α1 helix have relatively small CSP
values when titrated with monoubiquitin (Fig. 5, A and C).
When titrated with K63Ub2, however, the CSP values for
residues from the N-terminal end of the α1 helix are larger
(Fig. 5, B and D). The increased CSP values for residues at the
N-terminal end of the α1 helix in the presence of K63Ub2
compared to monoubiquitin suggest that these residues may

form a second binding site for the proximal ubiquitin of
K63Ub2 (Fig. 5, E and F).
To test the hypothesis that ASCC2 residues at the N-terminal end of the α1 helix bind the proximal ubiquitin of
K63Ub2, we made point mutations at ASCC2 residues E467,
S470, and L471 and assayed their effects on ASCC2 CUE
domain binding to K63Ub2. Although ITC experiments
showed that the afﬁnity of the ASCC2(465–521) L471A
mutant for K63Ub2 was nearly identical to that of WT
ASCC2(465–521) (Fig. 6A), the ASCC2 E467A mutant bound
3.6- to 5.0-fold more weakly, with a Kd in the range of 46.9 μM
to 65.4 μM (Fig. 6B). The ASCC2 S470R mutant bound with
J. Biol. Chem. (2022) 298(2) 101545
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Figure 4. The ASCC2 CUE domain binds K63Ub2 E64A/T66Aprox with reduced afﬁnity relative to WT K63Ub2. ITC data show that ASCC2(465–521)
binds WT K63Ub2 (A) with 3.5 to 7.0× greater afﬁnity than K63Ub2 E64A/T66Aprox (B). ASCC2, Activating Signal Cointegrator 1 Complex Subunit 2; CUE,
coupling of ubiquitin conjugation to ER degradation; ITC, isothermal titration calorimetry.

even lower afﬁnity, with an apparent Kd of 90.9 μM ± 23.1 μM
(Fig. 6C). An ASCC2 E467R/S470R double mutant bound
K63Ub2 with an apparent Kd of 92.6 μM ± 20.9 μM (Fig. 6D).
The decrease in K63Ub2 binding afﬁnity observed upon
mutating the α1 helix stands in contrast to the effect observed
upon altering other ASCC2 CUE domain regions that could
potentially interact with the proximal ubiquitin of K63Ub2,
such as the α2 helix, or the loop connecting the α2 and α3
helices, where mutations resulted in little change in binding
afﬁnity (Fig. S2). The decreased afﬁnity observed for the E467
and S470 mutant proteins is consistent with 1H,15N-HSQC
data (Fig. 5) suggesting that the ASCC2 CUE domain binds the
proximal ubiquitin of K63Ub2 using a second, previously
uncharacterized, interaction site located at the N-terminal end
of the α1 helix. The presence of a second binding site on the
ASCC2 CUE domain could account for the enhanced afﬁnity
of the ASCC2 CUE domain for K63Ub2 relative to monoubiquitin and the 1:1 stoichiometry of ASCC2 CUE:K63Ub2
binding (Fig. 2).
To test the functional importance of the N-terminal
portion of the ASCC2 CUE domain α1 helix in cells, we
studied the effect of an E467R/S470R double mutation on
the recruitment of ASCC2 to alkylation damage-induced
foci. As compared to WT ASCC2, the E467R/S470R
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double mutant had signiﬁcantly reduced ASCC2 foci after
alkylation damage was induced with methyl methanesulfonate (MMS) (Fig. 6, E and F). This mutant was expressed at
levels similar to the WT protein, suggesting that the defect is
not because of a loss of expression due to misfolding or other
global defect (Fig. S3). These results are consistent with a
role for the N-terminal portion of the ASCC2 CUE domain
α1 helix in its recruitment during the DNA damage
response.
Model of the ASCC2 CUE domain binding to K63-linked
diubiquitin
We modeled the interaction between the proximal ubiquitin of K63Ub2 and the ASCC2 CUE domain using the High
Ambiguity Driven protein–protein DOCKing (HADDOCK)
protein-docking server (16, 17). We ﬁrst generated a model of
the interaction between the ASCC2 CUE domain and the
distal ubiquitin based on the gp78 CUE:monoubiquitin
complex (PDB ID: 2LVO) (10) by superimposing residues 465
to 521 of the ASCC2 CUE domain structure (PDB ID: 2DI0)
on the gp78 CUE domain. Given the similarity between the
CSP values for the distal ubiquitin of K63Ub2 titrated with the
ASCC2 CUE domain (Fig. 3C) and the CSP values for
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Figure 5. The ASCC2 CUE domain uses conserved sequences from the α1 and α3 helices, along with the N-terminal end of the α1 helix, to bind
K63-linked polyubiquitin chains. Regions of the 1H-15N-HSQC spectra of 15N-labeled ASCC2(465–521) show that residues from the ASCC2 α1 helix (e.g.,
L468, L471, and Q474) exhibit larger CSPs when titrated with K63Ub2 (B) compared to monoubiquitin (A). CSP values recorded for all 15N-labeled
ASCC2(465–521) residues titrated with monoubiquitin or K63Ub2 are reported in Figure 5, C and D, respectively. A black bar indicates the resonance
disappeared during the titration. Coloring ASCC2(465–521) surface residues with CSP values greater than 1σ (yellow) and 2σ (red) in the presence of
monoubiquitin (E) and K63Ub2 (F) suggests that the N-terminal portion of the ASCC2 α1 helix may form a second ubiquitin-binding site for interacting with
K63-linked polyubiquitin chains. ASCC2, Activating Signal Cointegrator 1 Complex Subunit 2; CSP, chemical shift perturbation; CUE, coupling of ubiquitin
conjugation to ER degradation; HSQC, Heteronuclear Single Quantum Coherence.

monoubiquitin titrated with the gp78 CUE domain (10), it is
likely that these interactions are structurally similar. Distance
restraints based on NMR CSP data and mutagenesis data
were used by the HADDOCK server to guide the docking of
the proximal ubiquitin of K63Ub2 to the ASCC2 CUE
domain. ASCC2 residues E467 and S470, and proximal
ubiquitin residues E64 and T66, were speciﬁed as residues
likely to be at the binding interface based on the deleterious
effect of substitutions at these residues on binding (Figs. 4B
and 6, B–D). In addition, proximal ubiquitin residues with
CSP values greater than 2σ were also speciﬁed as likely to be
at the interface with ASCC2. These proximal ubiquitin residues include A46, G47, K48, Q49, and L71. The resulting
model of the ASCC2(465–521):K63Ub2 complex is shown in
Figure 7A. This model places the majority of the K63Ub2 and

ASCC2(465–521) residues with the largest CSP values at the
binding interface, as shown in Figure 7, B and C, respectively.

Discussion
The preferential binding of ASCC2 to K63-linked polyubiquitin chains stands in contrast to other CUE domain
proteins, which show more modest enhancement of binding to
monoubiquitin versus polyubiquitin and little selectivity
among polyubiquitin chain types (10, 12). We found that the
afﬁnity of the ASCC2 CUE domain for K63Ub2 is approximately 4- to 7-fold higher than its afﬁnity for monoubiquitin,
and that the ASCC2 CUE domain binds to diubiquitin and
tetraubiquitin in a ratio of one CUE domain per diubiquitin
(Fig. 2). Interactions with the distal ubiquitin are similar to
J. Biol. Chem. (2022) 298(2) 101545
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Figure 6. ASCC2 residues E467 and S470 bind the proximal ubiquitin of K63Ub2. A, the ASCC2(465–521) L471A mutant binds K63Ub2 with nearly the
same afﬁnity as WT ASCC2(465–521) (Fig. 4A). B, the ASCC2(465–521) E467A mutant, however, binds K63Ub2 approximately 3.6- to 5.0-fold more weakly
than WT ASCC2(465–521) and (C) the ASCC2(465–521) S470R mutant, and (D) the ASCC2(465–521) E467R/S470R double mutant bind approximately 7.0-fold
more weakly. These results suggest that ASCC2 residues E467 and S470 participate in the binding interaction with K63-linked polyubiquitin chains. E, HAtagged ASCC2, or the E467R/S470R mutant, were expressed in U2OS cells, then treated with 0.5 mM MMS for 6 h. Immunoﬂuorescence for HA and pH2A.X
were performed after extraction with Triton X-100, as shown, with Hoechst used as the nuclear counter stain. The scale bar represents 10 μm. F, quantiﬁcation of foci formation. N = 3 replicates and the error bars indicate ±S.D. of the mean. ASCC2, Activating Signal Cointegrator 1 Complex Subunit 2; MMS,
methyl methanesulfonate.

those observed for other CUE domains bound to monoubiquitin (8–12), whereas ASCC2 contacts the proximal
ubiquitin in a noncanonical manner using residues from the
N-terminal portion of the α1 helix (Figs. 5 and 6). By contrast,
CUE domains from other proteins, such as Cue1 and gp78,
make fewer contacts with adjacent ubiquitins within polyubiquitin chains and, accordingly, exhibit smaller enhancements in their afﬁnities for polyubiquitin chains compared to
monoubiquitin (10, 11). For example, the CUE domain from
the protein Cue1 binds to the I44 patch of the proximal
ubiquitin in K48Ub2 while also contacting G75 and the
C-terminus of the distal ubiquitin (11). The Kd for the Cue1
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CUE domain binding K48Ub2 is 95 μM compared to 173 μM
for binding to monoubiquitin (11). This enhancement is much
more modest than the 4- to 7-fold enhancement observed for
the ASCC2 CUE domain. The gp78 CUE domain contacts T66
of the proximal ubiquitin in K48Ub2 while binding the I44
patch of the distal ubiquitin, resulting in an enhancement in
afﬁnity for the distal ubiquitin in K48Ub2 relative to the
proximal ubiquitin (10). Overall, however, the gp78 CUE
domain binds K48Ub2 and monoubiquitin with virtually equal
afﬁnity of about 12.4 μM and 12.8 μM, respectively (10).
Despite the modest enhancement in afﬁnity for polyubiquitin
chains exhibited by the gp78 and Cue1 CUE domains,
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interacting with adjacent ubiquitins simultaneously is important for their biological functions. For these CUE domains, the
interactions described above properly position ubiquitin ligases to add to growing polyubiquitin chains (10, 11). For the
ASCC2 CUE domain, interactions with adjacent ubiquitins
strengthen the afﬁnity for ASCC2’s biologically relevant target,
K63-linked polyubiquitin chains (Fig. 2), and increase the
recruitment of the ALKBH3–ASCC repair complex to alkylation damage sites (Fig. 6, E and F).
Although the ASCC2 CUE domain has been shown to bind
K63Ub2 with enhanced afﬁnity relative to M1Ub2 and K48Ub2,
the structural basis for this selectivity has not been fully
elucidated. Linear polyubiquitin chains, and possibly

K48-linked polyubiquitin chains, can adopt similar conformations to the K63-linked polyubiquitin chain shown in
Figure 7 (14, 15) and interact with the same surfaces of the
ASCC2 CUE domain. However, the afﬁnity of the ASCC2 CUE
domain for M1Ub2 and K48Ub2 relative to K63Ub2 is much
weaker (Fig. 2). We speculate that ASCC2 CUE domain interactions with proximal ubiquitin residues near the K63 isopeptide linkage, including residues E64 and T66, contribute to
the selectivity for K63-linked polyubiquitin. Consistent with
this, we found that alanine substitutions of proximal ubiquitin
residues E64 and T66 reduced the afﬁnity for K63Ub2 by about
3.5- to 7.0-fold (Fig. 4). Other ubiquitin-binding domains
speciﬁc for K63-linked polyubiquitin, such as the myosin VI
MyUb domain, similarly contact the I44 patch of the distal
ubiquitin and proximal ubiquitin residues near the K63 isopeptide linkage, including T66 (18), suggesting that this may
be a general mechanism for imparting speciﬁcity. Furthermore, it is not known which proximal ubiquitin surface in
K63Ub2 interacts with the N-terminal portion of the ASCC2
CUE domain α1 helix and whether the proximal ubiquitins of
M1Ub2 and K48Ub2 are capable of making similar contacts.
Elucidating the structural details of the interactions between
K63Ub2 residues E64, T66, and the proximal ubiquitin as a
whole, with the ASCC2 CUE domain will be the subject of
continued investigation of the basis for ASCC2 domain
selectivity.

Experimental procedures
Plasmids for protein expression
ASCC2 constructs containing amino acids 457 to 525 or
465 to 521 were inserted into a pPROEX HTa vector with an
N-terminal polyhistidine tag followed by a tobacco etch virus
protease recognition sequence. Full-length ASCC2 was
inserted into the pET28 vector. WT ubiquitin residues 1 to 76
(wt Ub), along with mutant ubiquitin constructs containing
K48R/K63R substitutions (K48R/K63R Ub) or a D77 extension (D77 Ub), were inserted into the pET-3a vector.
Plasmids for cell-based studies

Figure 7. Model of the ASCC2(465–521):K63Ub2 complex. A, the ASCC2
CUE domain was superimposed onto the gp78 CUE domain structure in the
gp78 CUE:ubiquitin complex (PDB ID: 2LVO). The proximal ubiquitin of
K63Ub2 was docked to the complex using the HADDOCK server. In this
model, binding of the I44 patch of the distal ubiquitin to the hydrophobic
α1 and α3 sequence motifs of ASCC2, mediated by residues including L479
and L506, positions the C-terminal tail of the distal ubiquitin to interact with
the α3 helix of ASCC2. Isopeptide bond formation at proximal ubiquitin
residue K63 (dashed line) places adjacent proximal ubiquitin residues E64
and T66 within binding distance of the ASCC2 CUE domain. The proximal
ubiquitin of K63Ub2 docks against the N-terminal end of the CUE domain α1
helix, where ASCC2 residues E467 and S470 interact with proximal ubiquitin
residues. In B and C, the model of the ASCC2(465–521):K63Ub2 complex is
shown with K63Ub2 or ASCC2(465–521) in surface representation, respectively. The residues with CSP values greater than 1σ are colored yellow and
residues with CSP values greater than 2σ are colored red, according to the
data in Figures 3, C and D and 5D. ASCC2, Activating Signal Cointegrator 1
Complex Subunit 2; CSP, chemical shift perturbation; CUE, coupling of
ubiquitin conjugation to ER degradation; HADDOCK, High Ambiguity Driven
protein–protein DOCKing.

Full-length human ASCC2 cDNA cloned into pENTR-3C
and pET-28a-Flag was previously described (7). The ASCC2
E467R/S470R mutant cDNA was synthesized (IDT), cloned
into pENTR-3C and pET-28a-Flag, and conﬁrmed by Sanger
sequencing. For human cell expression, ASCC2 E467R/S470R
was subcloned into pHAGE-CMV-3XHA using Gateway
recombination.
Expression and puriﬁcation of the ASCC2 CUE domain
BL21 DE3 Escherichia coli cells were transformed with
pPROEX HTa vector containing the ASCC2 constructs, plated
on LB agar containing 100 μg/ml ampicillin, and incubated
overnight at 37  C. Single colonies were used to inoculate 5-ml
aliquots of LB media with 100 μg/ml ampicillin. The 5-ml
cultures were grown overnight at 37  C with 250 rpm
shaking until saturation. The 5-ml colonies were used to
inoculate 1-l cultures of LB media with 100 μg/ml ampicillin,
J. Biol. Chem. (2022) 298(2) 101545
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which were grown at 37  C with 250 rpm shaking until
reaching an A600 between 0.5 and 0.8. Protein expression was
induced by adding 0.5 mM IPTG and allowed to continue
overnight at 16  C with 250 rpm shaking. After protein
expression, the cells were pelleted by centrifugation, resuspended in a buffer consisting of 50 mM Tris pH 7.5 and 1 mM
PMSF, and lysed by sonication on ice. Cell lysate was centrifuged at 17,500g for 30 min at 4  C, passed through a ﬁlter with
0.22 μm pore size, and loaded onto a 5-ml HisTrap column
(Cytiva life sciences) that had been equilibrated in buffer A
(50 mM Tris pH 7.5, 250 mM NaCl, 10 mM imidazole, and
200 μM Tris (2-carboxyethyl) phosphine (TCEP)). The Histagged ASCC2 CUE domain that was retained by the
HisTrap column was eluted by running a gradient from 0% to
100% buffer B (50 mM Tris pH 7.5, 250 mM NaCl, 400 mM
imidazole, and 200 μM TCEP) over 100 ml. The fractions
judged to contain His-tagged ASCC2 CUE domain by gel
electrophoresis were combined and incubated with His-tagged
tobacco etch virus protease while being dialyzed in buffer A
overnight at 4  C. The dialyzed sample was then repassed over
a HisTrap column equilibrated in buffer A, and the ﬂowthrough containing the untagged ASCC2 CUE domain was
collected and concentrated to less than 5 ml. The concentrated
ASCC2 CUE domain solution was passed over a Superdex 75
16/60 size-exclusion column (Cytiva life sciences) equilibrated
in 20 mM Hepes pH 7.6, 150 mM NaCl, and 200 μM TCEP.
The ASCC2 CUE domain eluted from the column as a single
peak roughly 85 ml after injection.
Expression and puriﬁcation of full-length ASCC2
E. coli Rosetta (DE3) cells were transformed with pET-28
vector containing full-length ASCC2 and grown on LB agar
plates with kanamycin and chloramphenicol. The resulting
colonies were used to inoculate 5 ml cultures of LB media with
kanamycin and chloramphenicol, which were grown overnight
at 37  C and 250 rpm shaking until reaching saturation. The
5-ml cultures were used to inoculate 1-l cultures of LB media
with kanamycin and chloramphenicol that were grown at
37  C and 250 rpm shaking until reaching an A600 between 0.5
and 0.8. Once the cells had reached the appropriate density,
the temperature was lowered to 16  C, and ASCC2 expression
was induced by adding 500 μl of 1 M IPTG. After approximately 16 h, the cells were harvested by centrifuging at
5000 rpm for 20 min. The cells were resuspended in 100 ml of
lysis buffer (50 mM Tris pH 7.5, 250 mM NaCl, 20 mM
imidazole, 3 mM β-mercaptoethanol, 2 μM PMSF, and one
cOmplete Mini, EDTA-free protease-inhibitor tablet (Roche)),
lysed using a microﬂuidizer, and then centrifuged at
14,000 rpm for 30 min at 4  C to separate the soluble and
insoluble fractions. The soluble fraction was then passed
through syringe ﬁlters with 0.45-micron and 0.22-micron pore
sizes before being loaded onto a 5-ml HisTrap column (Cytiva
life sciences) that had been equilibrated in buffer A (50 mM
Tris pH 7.5, 250 mM NaCl, 20 mM imidazole, and 3 mM
β-mercaptoethanol). His-tagged, full-length ASCC2 was eluted
from the column using a gradient from 0% to 100% buffer B
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(50 mM Tris pH 7.5, 250 mM NaCl, 400 mM imidazole, and
3 mM β-mercaptoethanol) over 50 ml. Fractions containing
full-length ASCC2, as determined by SDS-PAGE, were
concentrated to less than 5 ml total volume and passed over a
Superdex 200 16/60 size-exclusion column (Cytiva Life Sciences) that had been equilibrated in a buffer consisting of
20 mM Hepes pH 7.5, 150 mM NaCl, and 200 μM TCEP. Fulllength ASCC2 eluted from the Superdex 200 16/60 sizeexclusion column 60 to 70 ml after injection.
Expression and puriﬁcation of monoubiquitin
BL21 DE3 E. coli cells were transformed with pET-3a
vector containing the ubiquitin constructs, plated on LB
agar containing 100 μg/ml ampicillin, and incubated overnight at 37  C. Single colonies were used to inoculate 5-ml
aliquots of LB media with 100 μg/ml ampicillin. The 5-ml
cultures were grown overnight at 37  C with 250 rpm
shaking until saturation. The 5-ml colonies were used to
inoculate 1-l cultures of LB media with 100 μg/ml ampicillin,
which were grown at 37  C with 250 rpm shaking until
reaching an A600 between 0.5 and 0.8. Protein expression was
induced by adding 0.5 mM IPTG and allowed to continue
overnight at 16  C with 250 rpm shaking. After protein
expression, the cells were pelleted by centrifugation, resuspended in a buffer consisting of 50 mM Tris pH 7.5 and
1 mM PMSF, and lysed by sonication on ice. Cell lysate was
centrifuged at 17,500g for 30 min at 4  C, after which the
soluble fraction was separated and slowly stirred on ice. To
the stirring soluble fraction, 1% (v/v) of 70% perchloric acid
was added dropwise until the solution turned a milky white.
This solution was centrifuged at 17,500g for 30 min at 4  C,
after which the soluble fraction containing the ubiquitin was
separated from the pellet. The soluble fraction was then
subjected to multiple rounds of dialysis in 10 mM Tris pH 7.6
until reaching a neutral pH.
Conjugation and puriﬁcation of polyubiquitin chains
Polyubiquitin chains were assembled enzymatically by
combining monoubiquitin (>1 mM), human UBE1 enzyme
(500 nM), and Saccharomyces cerevisiae Ubc13/Mms2
(2.5 μM) in a solution containing 50 mM Hepes pH 7.5,
10 mM MgCl2, 1 mM TCEP, and 10 mM ATP. To limit the
chain length to diubiquitin, K48R/K63R ubiquitin and D77
ubiquitin can be substituted for WT ubiquitin in the reaction
mixture (19). K48R/K63R ubiquitin will occupy the distal
position in K63Ub2, and D77 ubiquitin will occupy proximal
position in K63Ub2. Human UBE1 and S. cerevisiae Ubc13/
Mms2 enzymes were expressed and puriﬁed, as previously
described (20, 21). The reaction mixture was incubated
overnight at 37  C and then diluted 10-fold in buffer A
(50 mM ammonium acetate pH 4.5 and 50 mM NaCl) and
loaded onto a monoS 10/100 GL column (Cytiva life sciences)
equilibrated in buffer A. The ubiquitin species retained by the
column were eluted by running a gradient from 0 to 100%
buffer B (50 mM ammonium acetate pH 4.5 and 600 mM
NaCl) over 300 ml.
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Isothermal titration calorimetry binding experiments and data
analysis
For ITC experiments involving K63Ub2, distal ubiquitins
contained K48R/K63R mutations and proximal ubiquitins
contained D77 mutations to control the polyubiquitin chain
length, as described above. For the monoubiquitin-binding
experiment in Figure 2A, K48R/K63R ubiquitin was used.
Before each ITC experiment, the proteins were dialyzed
overnight in a solution of 20 mM Hepes pH 7.5, 150 mM
NaCl, and 200 μM TCEP. Using a MicroCal iTC200 instrument (Malvern), titrations were conducted using a series
of 2-μl injections each lasting 4 s, with a minimum of 2 min
between injections. Fitting was performed using Origin 7
SR4 (OriginLab). Many of the relatively weak binding interactions produced nonsigmoidal isotherms in which the N
values could not be accurately determined. Therefore, we in
addition provide the range of Kd values when ﬁxing N = 1.
The N value was set to one in these calculations because
the sigmoidal isotherms from the higher afﬁnity binding
interactions with the ASCC2 CUE domain and diubiquitin
consistently produced N values of approximately one,
reﬂecting the one ASCC2 CUE domain per one K63Ub2
binding ratio. The N values were ﬁxed by altering the active
concentrations in the cell and syringe during ﬁtting. The
ﬁrst Kd value in the range corresponds to varying the active
concentration in the cell, and the second Kd value in the
range corresponds to varying the active concentration in the
syringe.
Chemical shift mapping experiments
15

N-labeled ASCC2(465–521) and K63-linked diubiquitin
were made following similar expression and puriﬁcation
protocols to those described above, however, after reaching
an A600 between 0.5 and 0.8, the 1-l aliquots of cells were
pelleted, washed with M9 salts, and resuspended in one-third
the original volume of minimal media containing 15N-labeled
ammonium chloride. The resuspended cells recovered for 1 h
at 37  C with 225 rpm shaking before proceeding with the
induction of protein expression, as described above. Performing the 15N-labeling procedure with either K48R/K63R
ubiquitin or D77 ubiquitin and then conjugating the
15
N-labeled ubiquitin species to the unlabeled ubiquitin
species allowed for the production of K63Ub2 with the
15
N-labeled ubiquitin at either the distal or the proximal
position, respectively.
1 15
H, N-HSQC spectra of ASCC2(465–521) and ubiquitin
were recorded using a 600 MHz AVANCE II NMR system at
the Biomolecular NMR Center at Johns Hopkins University.
Resonances in the 1H,15N-HSQC spectra of ubiquitin were
assigned based on data from Dr Carlos Castañeda (personal
communication).
Resonance
assignments
for
the
ASCC2(465–521) 1H,15N-HSQC spectra were obtained from
3D 15N-edited 1H-1H NOESY-HSQC and 15N-edited 1H-1H
TOCSY-HSQC spectra. NMR data were processed using
nmrPipe software (22), and CSP values were measured using
qﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
the formula d ¼ δ2H þð0:15δN Þ2 by the program CcpNmr

Analysis (23) on the NMRBox platform (24). The CSP values
in Figure 3 were measured for the titration of 100 μM K63Ub2,
15
N-labeled on the distal ubiquitin in Figure 3A and
15
N-labeled on the proximal ubiquitin in Figure 3B, with
30 μM, 100 μM, 200 μM, and 500 μM ASCC2(465–521) at 20

C. The CSP values in Figure 5A were measured for 20 μM
15
N-labeled ASCC2(465–521) alone and in the presence of
681 μM K48R/K63R ubiquitin at 40  C in a buffer consisting of
20 mM Tris pH 7.0, 100 mM NaCl, and 200 μM TCEP. The
CSP values in Figure 5B were measured for the titration of
20 μM 15N-labeled ASCC2(465–521) with 6 μM, 20 μM, and
40 μM K63Ub2 at 40  C in a buffer consisting of 20 mM Tris
pH 7.0, 100 mM NaCl, and 200 μM TCEP. In Figures 3 and 5,
resonances that disappeared during the course of the titration
are marked by a black bar and assigned values of 0.35 or
0.30 ppm, respectively. NMR data, chemical shift assignments,
and CSP values for 15N-labeled ASCC2 CUE domain titrated
with monoubiquitin and K63Ub2 have been deposited to the
Biological Magnetic Resonance Data Bank (25) as entries
51,130 and 51,139, respectively. NMR data, chemical shift assignments, and CSP values for 15N-labeled K63Ub2 titrated
with the ASCC2 CUE domain have been deposited to the
Biological Magnetic Resonance Data Bank (25) as entries
51,145 (5N-labeled on the proximal ubiquitin) and 51,146
(15N-labeled on the distal ubiquitin).
Determining ASCC2 CUE domain binding afﬁnity for
monoubiquitin using CSP data
The program CcpNmr Analysis (23) used information from
the titration of 15N-labeled ASCC2(465–521) with monoubiquitin, as described in the previous section, to determine
the Kd value for ASCC2(465–521) binding monoubiquitin
qﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
using the formula y ¼ AðB þx − ðBþxÞ2 −4xÞ where y = δobs,
A = δ∞/2, B = 1 + Kd/a, a = [ASCC2]tot, b = [Ub]tot, and x =
b/a. The Kd value of 39.6 μM ± 1.6 μM reported in Fig. S1 is
the average of the Kd values determined for residues L478,
L479, Q500, and L506. These four residues have the largest
CSP values recorded for the titration of 15N-labeled
ASCC2(465–521) with monoubiquitin and are all predicted to
be at the ASCC2:ubiquitin-binding interface.
Modeling the ASCC2 CUE:K63Ub2 complex using PyMOL and
the HADDOCK server
The PyMOL molecular visualization system (26) and the
HADDOCK protein-docking server (16, 17) were used to
model the interaction between the ASCC2 CUE domain and
K63Ub2. First, the interaction between the ASCC2 CUE
domain and the distal ubiquitin was modeled based on the
solution structure of the gp78 CUE:monoubiquitin complex
(PDB ID: 2LVO) (10). PyMOL was used to superimpose the
solution structure of the ASCC2 CUE domain (PDB ID: 2DI0)
with the structure of the gp78 CUE domain in the ubiquitinbound complex. The HADDOCK server was then used to
model the interaction between the proximal ubiquitin and the
ASCC2 CUE domain. To guide the docking experiment,
J. Biol. Chem. (2022) 298(2) 101545
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proximal ubiquitin residues with CSP values greater than 2σ,
or resonances that disappeared during the NMR titration, were
identiﬁed as “active” residues. For the ASCC2 CUE domain,
residues outside of the conserved hydrophobic patch that
decrease the ubiquitin-binding afﬁnity when mutated were
identiﬁed as active. For the reported model, the active proximal ubiquitin residues were A46, G47, K48, Q49, E64, T66,
and L71, and the active ASCC2 CUE domain residues were
E467 and S470. In addition, a distance restraint of 1.32 Å
between the carbonyl carbon of G76 of the distal ubiquitin and
the ε-amino group of K63 of the proximal ubiquitin was used
to approximate the isopeptide linkage in the diubiquitin chain.
The reported model is the best structure from the highest
scoring cluster.
Immunoﬂuorescence analysis of HA-tagged ASCC2
All immunoﬂuorescence analysis was performed in U2OS
cells using WT and mutant forms of ASCC2, expressed in the
pHAGE-CMV-3xHA lentivirus (7). Three days after transduction, the cells were treated with 500 μM MMS in complete
Dulbecco’s modiﬁed Eagle’s medium (DMEM) media for 6 h.
U2OS cells were washed once with ice-cold PBS, then
extracted with 1× PBS containing 0.2% Triton X-100 and
protease inhibitors (Pierce) for 10 to 20 min on ice before
ﬁxation with 3.2% paraformaldehyde. The cells were then
washed extensively with immunoﬂuorescence wash buffer (1×
PBS, 0.5% NP-40, and 0.02% NaN3), then blocked with
immunoﬂuorescence blocking buffer (immunoﬂuorescence
wash buffer plus 10% FBS) for at least 30 min. Primary antibodies were diluted in immunoﬂuorescence blocking buffer
overnight at 4  C. After staining with secondary antibodies
(conjugated with Alexa Fluor 488 or 594; Millipore) and
Hoechst 33342 (Sigma-Aldrich), where indicated, samples
were mounted using Prolong Gold mounting medium (Invitrogen). Epiﬂuorescence microscopy was performed on an
Olympus ﬂuorescence microscope (BX-53) using an ApoN
60×/1.49 numerical aperture oil immersion lens or an UPlanSApo 100×/1.4 numerical aperture oil immersion lens and
cellSens Dimension software. Raw images were exported into
Adobe Photoshop, and for any adjustments in image contrast
or brightness, the levels function was applied. For foci quantiﬁcation, at least 100 cells were analyzed in triplicate.

Data availability
NMR data reported in this article have been deposited in the
Biological Magnetic Resonance Data Bank as entries 51,130
(15N-labeled ASCC2 CUE domain interacting with monoubiquitin), 51,139 (15N-labeled ASCC2 CUE domain interacting with K63Ub2), 51,145 (K63Ub2 15N-labeled on the
proximal ubiquitin interacting with the ASCC2 CUE domain),
and 51,146 (K63Ub2 15N-labeled on the distal ubiquitin
interacting with the ASCC2 CUE domain).
Supporting information—This
information.
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